Adonis vs Aspirion
Two Denials & Appeals vendors, side by side. Facts from public sources; judgments are ours.
At a glance
Derived from public facts · a rough scale, not a ranking
| Adonis | Aspirion | |
|---|---|---|
| Pricing model | Not published · Custom quotes via demo | Contingency (pay from recoveries) · Success-based, paid from recovered revenue |
| Speed to go live | API connection to EHR, billing, payer portals | Data feeds set up, they work inventory |
| Automation model | Autonomous agents · agents plus revenue intelligence alerts | Tech-enabled service · Attorneys and AI recover complex claims |
| Built for | Mid-size groups, Enterprise systems, Billing companies | Enterprise systems |
| Security posture | HIPAA | HITRUST, HIPAA |
| Company maturity | 4 yrs (est. 2022) | 14 yrs (est. 2012) |
| Financial backing | $95M+ · Series C | PE-owned (Linden Capital Partners) |
| Named customers | 5 named | None public |
| Published results | No public numbers | No public numbers |
| Documented integrations | 5 listed | None documented |
| Third-party validation | None found | KLAS / analyst cited |
Bottom line
- Pick Adonis if you want AI agents and revenue analytics layered onto your existing EHR and billing stack without replacing it.
- Pick Aspirion if you're a hospital with denials, MVA, workers' comp, or VA claims you can't work in-house and you'd rather pay only from what gets recovered.
Adonis
Revenue intelligence and denial prevention
- Founded
- 2022
- HQ
- New York, NY
- Stage
- Series C
- Raised
- $95M+
What it does
- Real-time revenue intelligence dashboards across the claim lifecycle
- Detects denials, underpayments, and revenue leakage automatically
- AI agents work claims: status checks, appeals, resubmissions
- Prioritized worklists route staff to highest-value tasks
- Alerts on payer behavior changes before revenue impact spreads
- Orchestration layer sits on top of existing billing systems
Where it's strong
- Analytics-first approach surfaces why revenue is leaking, not just that it is, which most billing systems cannot do.
- AI agents now autonomously progress claims, and traction is real: 4x revenue growth in 2025 with Mount Sinai as a flagship customer.
- Works on top of your existing EHR and billing stack rather than replacing it.
What buyers should weigh
- It augments your RCM team rather than replacing it; you still need billers, unlike full-service RCM vendors.
- The company is four years old and scaling fast, so expect some product churn and evolving packaging.
- Value depends on claim volume; small practices may not generate enough data to justify the platform.
Named customers
Mount Sinai Health System · Allied Digestive Health · ApolloMD · Seaview Orthopaedic & Medical Associates · Tend Dental
Integrations
Aspirion
Complex claims and denials recovery for hospitals
- Founded
- 2012
- HQ
- Columbus, GA
- Stage
- PE-owned (Linden Capital Partners)
- Raised
- n/a
What it does
- Clinical and technical denials appeals with attorney support
- Motor vehicle accident and workers' compensation claims
- VA, TRICARE, and out-of-state Medicaid billing
- Underpayment and zero-balance review
- Aged AR resolution
- AI-assisted appeal generation and claim prioritization
Where it's strong
- Named 2025 Best in KLAS for denials management, its second consecutive year, which is rare third-party validation in this segment.
- In-house attorneys and clinicians handle payer disputes most internal RCM teams cannot staff, and it serves over 140 clients including many of the largest US health systems.
- Contingency-style pricing ties fees to actual recoveries, keeping downside risk low for the provider.
What buyers should weigh
- It is a recovery service that works claims after the fact; it will not fix the upstream registration or coding problems causing the denials.
- The company has absorbed several acquisitions (Boost Healthcare, FIRM, Continuum), so ask which team and toolset will actually work your inventory.
- Contingency fees on high-dollar complex claims add up; model the effective rate against building internal capacity.
Compare against the rest of Denials & Appeals
Deciding between these two?
First Pass tracks Denials & Appeals every week: funding, launches, and what changed since this page was written.